Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UROCOM-R1 Plus UROCOM-R2 Combination Therapy in Benign Prostatic Hyperplasia
NCT07870759Phase 3Not yet recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Aug 2027
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Finasteride+Tamsulosin, Finasteride and Tamsulosin (3 arms). Primary endpoint: International Prostate Symptom Score at 48 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
finasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07870759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870759.